Abstract
Objective: to summarize the available data on clinical trials of vaccines based on mRNA encoding neoantigens. Material and Methods. Data were searched on https://classic.clinicaltrials.gov and https://pubmed.ncbi.nlm.nih.gov/, from January 2013 to May 2024 using the keywords “neoantigen” and “vaccine”, and the information on mRNA-based drugs was then selected. Of the 148 studies retrieved, 54 were selected to write a systematic review. Results. A bibliometric analysis of data in the field of therapeutic cancer vaccines from 2013 to 2024 showed that the majority of studies focused on mRNA vaccines encoding neoantigens. this paper presents a brief description of the mRNA platform and provides an overview of clinical trials of anticancer mRNA vaccines from 2013 to 2024. Preparations of leading biotech firms in Europe and the USA involved in the development of anticancer mRNA vaccines, such as Cevumeran (BioNTech), mRNA-4157/V940 (Moderna), as well as vaccines from companies in the PRC - Stemirna Therapeutics, NeoCura, Hangzhou Neoantigen Therapeutics, etc. - are reviewed. Conclusion. The use of vaccine technology based on mRNAs encoding tumor neoantigens can significantly increase the potential of antitumor immunotherapy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call